WP
NBIX icon

Woodline Partners’s Neurocrine Biosciences NBIX Stock Holding History

Woodline Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$915K Buy
5,429
+1,539
+40% +$228K ﹤0.01% 924
2026
Q1 		$512K Sell
3,890
-68,408
-95% -$9.08M ﹤0.01% 961
2025
Q4 		$10.3M Buy
+72,298
New +$10.5M 0.04% 458
2025
Q3 		– Sell
-68,937
Closed -$8.66M – 998
2025
Q2 		$8.66M Sell
68,937
-63,955
-48% -$7.33M 0.05% 455
2025
Q1 		$14.7M Buy
+132,892
New +$16.8M 0.1% 286
2024
Q3 		– Sell
-14,011
Closed -$1.93M – 673
2024
Q2 		$1.93M Sell
14,011
-109,231
-89% -$15M 0.02% 418
2024
Q1 		$17M Buy
123,242
+21,960
+22% +$3M 0.16% 194
2023
Q4 		$13.3M Sell
101,282
-201,803
-67% -$23.2M 0.15% 198
2023
Q3 		$34.1M Sell
303,085
-849,104
-74% -$89.4M 0.4% 61
2023
Q2 		$109M Buy
1,152,189
+753,495
+189% +$73.6M 1.29% 9
2023
Q1 		$40.4M Buy
398,694
+90,283
+29% +$9.39M 0.55% 35
2022
Q4 		$36.8M Buy
+308,411
New +$36.1M 0.49% 41
2022
Q2 		– Sell
-259,635
Closed -$24.3M – 855
2022
Q1 		$24.3M Buy
259,635
+131,992
+103% +$11.2M 0.4% 72
2021
Q4 		$10.9M Sell
127,643
-502,194
-80% -$46.2M 0.16% 184
2021
Q3 		$60.4M Buy
629,837
+244,783
+64% +$23.1M 0.99% 18
2021
Q2 		$37.5M Buy
+385,054
New +$36.9M 0.7% 34
2020
Q1 		– Sell
-71,496
Closed -$7.68M – 162
2019
Q4 		$7.68M Buy
+71,496
New +$7.49M 0.31% 79

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Woodline Partners's NBIX Position: Q2 2026 in Review

Woodline Partners increased its Neurocrine Biosciences (NBIX) stake by 40% in Q2 2026, buying an estimated $228K and bringing the position to 5,429 shares worth $915K. The position accounts for ﹤0.01% of the portfolio, ranked #924.

Woodline Partners first reported a position in NBIX in Q4 2019 and has held it in 17 quarters since. The position peaked at $109M in Q2 2023. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Woodline Partners held 5,429 shares of Neurocrine Biosciences worth $915K as of Q2 2026.
  • Woodline Partners bought 1,539 Neurocrine Biosciences shares in Q2 2026, an estimated $228K.
  • Neurocrine Biosciences made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #924 holding.
  • Woodline Partners first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 17 quarters since.
  • Woodline Partners's Neurocrine Biosciences position peaked at $109M in Q2 2023.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.